Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643527 | 0.85 | FFAR1 (0.47) | GRM5 | |
| SCHEMBL6885194 | 0.82 | IL4I1 (0.53) | GRM2 | |
| SCHEMBL1644490 | 0.78 | FFAR1 (0.45) | GRM5GRM2 | |
| SCHEMBL1902361 | 0.78 | FFAR1 (0.51) | GRM5 | |
| SCHEMBL17111508 | 0.73 | NTRK1 (0.45) | GRM2 | |
| SCHEMBL531434 | 0.72 | GRM2 (0.52) | GRM2 | |
| SCHEMBL14480816 | 0.72 | SCN1A (0.56) | GRM5 | |
| SCHEMBL4519506 | 0.70 | GRM2 (0.51) | GRM2 | |
| SCHEMBL20695806 | 0.70 | KDM4E (0.44) | GRM2 | |
| SCHEMBL6888436 | 0.69 | FAAH (0.45) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493856-B1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN LA ROCHE (CH) | 2016-04-27 | — | — | EP | claimed |
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| EP-2493856-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. Hoffmann-La Roche AG (CH) | 2012-09-05 | — | — | EP | claimed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | claimed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | claimed |
| EP-2493856-B1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN LA ROCHE (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-8716316-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716316-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716316-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130131056-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131056-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131056-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2493856-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. Hoffmann-La Roche AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | GRM5 1/4885GRM2 3/4885 |
| US-20130131056-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | GRM5 1/4885GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.